Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

SAN ANTONIO, Texas, May 11, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced that it will report financial results for the first quarter ended March 31, 2026, after market close on Thursday, May 14, 2026. Management will host a conference call and webcast to discuss the Company's financial results and provide a business update.